RecruitingNCT05103254
Bempedoic Acid Pregnancy Surveillance Program
A Post-marketing, Long-term, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Women Exposed to Bempedoic Acid or Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) During Pregnancy
Sponsor
Esperion Therapeutics, Inc.
Enrollment
20 participants
Start Date
Sep 1, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
Bempedoic acid pregnancy surveillance program
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria1
- Exposure to at least 1 dose of bempedoic acid or bempedoic acid/ezetimibe FCDP at any time during pregnancy (from first day of last menstrual period \[LMP\] to pregnancy outcome
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBempedoic Acid
Bempedoic Acid 180 MG
DRUGBempedoic Acid / Ezetimibe
Bempedoic Acid 180 MG / Ezetimibe 10 MG
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05103254
Related Trials
PREgnancy and FERtility Registry
NCT0289516523 locations
MitoQ to Improve Vascular Funciton in Preeclampsia
NCT072292611 location
Probiotic Supplementation in Optimizing Iron and Hematological Status Among Pregnant Females
NCT070768491 location
Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia
NCT029890251 location
Efficacy and Adverse Side Effects of Two Forms of Iron in Pregnancy
NCT060149832 locations